abcam

Product datasheet

Anti-Lamin A antibody ab26300

KO VALIDATED

21 Abreviews 104 References 7 Images

Overview

Product name	Anti-Lamin A antibody
Description	Rabbit polyclonal to Lamin A
Host species	Rabbit
Specificity	Replenishment batches of ab26300 are tested in WB. Previous batches were additionally validated in ICC/IF. This application is still expected to work and is covered by our Abpromise guarantee.
Tested applications	**Suitable for:** ICC/IF, WB
Species reactivity	**Reacts with:** Mouse, Rat, Human **Predicted to work with:** Chicken, Pig
Immunogen	Synthetic peptide conjugated to KLH derived from within residues 550 to the C-terminus of Human Lamin A. Read Abcam's proprietary immunogen policy (Peptide available as **ab27812**.)
Positive control	ab26300 gave a positive result in the following Whole Cell Lysates A431 NIH 3T3 PC12 ICC-IF: Hela cells
General notes	The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage buffer	pH: 7.40 Preservative: 0.02% Sodium azide Constituent: PBS

Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.

Purity Immunogen affinity purified

Clonality Polyclonal

Isotype IgG

Applications

The Abpromise guarantee Our **Abpromise guarantee** covers the use of ab26300 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
ICC/IF	★★★★★ (4)	Use a concentration of 1 µg/ml.
WB	★★★★★ (14)	Use a concentration of 1 µg/ml. Detects a band of approximately 76 kDa (predicted molecular weight: 74 kDa).

Target

Function Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Play an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics.
Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.

Tissue specificity In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle celle (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.

Involvement in disease Defects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 2 (EDMD2) [MIM:181350]. A degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Defects in LMNA are the cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. A disorder characterized by the loss of subcutaneous adipose tissue in the lower parts of the body (limbs, buttocks, trunk). It is accompanied by an accumulation of adipose tissue in the face and neck causing a double chin,

fat neck, or cushingoid appearance. Adipose tissue may also accumulate in the axillae, back, labia majora, and intraabdominal region. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus after age 20 years, hypertriglyceridemia, and low levels of high density lipoprotein cholesterol.
Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.
Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.
Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging. Note=HGPS is caused by the toxic accumulation of a mutant form of lamin-A/C. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. Progerin lacks the conserved ZMPSTE24/FACE1 cleavage site and therefore remains permanently farnesylated. Thus, although it can enter the nucleus and associate with the nuclear envelope, it cannot incorporate normally into the nuclear lamina.
Defects in LMNA are the cause of cardiomyopathy dilated with hypergonadotropic hypogonadism (CMDHH) [MIM:212112]. A disorder characterized by the association of genital anomalies, hypergonadotropic hypogonadism and dilated cardiomyopathy. Patients can present other variable clinical manifestations including mental retardation, skeletal anomalies, scleroderma-like skin, graying and thinning of hair, osteoporosis. Dilated cardiomyopathy is characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia.
Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, progeroide appearance, partial alopecia, soft tissue calcinosis, joint contractures, and partial lipodystrophy with loss of subcutaneous fat from the extremities. Adipose tissue in the face, neck and trunk is normal or increased.
Defects in LMNA are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also known as restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
Defects in LMNA are the cause of heart-hand syndrome Slovenian type (HHS-Slovenian) [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.
Defects in LMNA are the cause of muscular dystrophy congenital LMNA-related (CMD-LMNA) [MIM:613205]. It is a form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.

Sequence similarities	Belongs to the intermediate filament family.
Post-translational modifications	Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations. Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin-A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage. Sumoylation is necessary for the localization to the nuclear envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
Cellular localization	Nucleus. Nucleus envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.

Images



Immunocytochemistry/ Immunofluorescence - Anti-Lamin A antibody (ab26300)

ab26300 staining Lamin A in HeLa cells. The cells were fixed with 100% methanol (5 min), permeabilized with 0.1% PBS-Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at 4°C with ab26300 at 5µg/ml and **ab7291**, Mouse monoclonal [DM1A] to alpha Tubulin - Loading Control. Cells were then incubated with **ab150081**, Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (Alexa Fluor® 488), pre-adsorbed at 1/1000 dilution (shown in green) and **ab150120**, Goat polyclonal Secondary Antibody to Mouse IgG - H&L (Alexa Fluor® 594), pre-adsorbed at 1/1000 dilution (shown in pseudocolour magenta). Nuclear DNA was labelled with DAPI (shown in blue). Also suitable in cells fixed with 4% paraformaldehyde (10 min).Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.



Western blot - Anti-Lamin A antibody (ab26300)

Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: Lamin A knockout HAP1 cell lysate (20 µg)
Lane 3: A431 cell lysate (20 µg)
Lane 4: NIH3T3 cell lysate (20 µg)

Lanes 1 - 4: Merged signal (red and green). Green - ab26300 observed at 76 kDa. Red - loading control, **ab8245**, observed at 37 kDa.

ab26300 was shown to recognize Lamin A in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when Lamin A knockout samples were examined. Wild-type and Lamin A knockout samples were subjected to SDS-PAGE. ab26300 1ug/ml and **ab8245** (loading control to GAPDH) at a dilution of 1/1000 were incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (**ab216773**) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (**ab216776**) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.



Western blot - Anti-Lamin A antibody (ab26300)
This image is courtesy of an anonymous abreview.

Anti-Lamin A antibody (ab26300) at 1/1000 dilution + HeLa whole cell extract at 100 µg

Secondary
Goat anti-Rabbit IgG (H+L) HRP Conjugate at 1/10000 dilution

Developed using the ECL technique.

Predicted band size: 74 kDa
Observed band size: 76 kDa

Exposure time: 15 seconds

Blocking: 5% milk for 30 minutes at 22°C



Western blot - Anti-Lamin A antibody (ab26300)

This image is courtesy of an anonymous Abreview

All lanes : Anti-Lamin A antibody (ab26300) at 1/1000 dilution

Lane 1 : Mouse NIH-3T3 cells - cytosolic fraction
Lane 2 : Mouse NIH-3T3 cells - nuclear fraction

Lysates/proteins at 25 µg per lane.

Secondary
All lanes : HRP conjugated Goat anti-rabbit at 1/5000 dilution

Developed using the ECL technique.

Performed under reducing conditions.

Predicted band size: 74 kDa
Observed band size: 76 kDa

Exposure time: 10 seconds



Western blot - Anti-Lamin A antibody (ab26300)

Anti-Lamin A antibody (ab26300) at 1 µg/ml + A-431 whole cell lysate (**ab7909**) at 20 µg

Secondary
IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/15000 dilution

Performed under reducing conditions.

Predicted band size: 74 kDa
Observed band size: 76 kDa
Additional bands at: 68 kDa (possible degradation product)



Western blot - Anti-Lamin A antibody (ab26300)

All lanes : Anti-Lamin A antibody (ab26300) at 1 µg/ml

Lane 1 : Recombinant Human Lamin A protein (**ab83472**) at 0.1 µg
Lane 2 : Recombinant Human Lamin A protein (**ab83472**) at 0.01 µg

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (**ab97080**) at 1/5000 dilution

Developed using the ECL technique.

Performed under reducing conditions.

Predicted band size: 74 kDa

Exposure time: 10 seconds



Western blot - Anti-Lamin A antibody (ab26300)

All lanes : Anti-Lamin A antibody (ab26300) at 1 µg/ml

Lane 1 : NIH/3T3 whole cell lysate (**ab7179**)
Lane 2 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate

Lysates/proteins at 10 µg per lane.

Secondary
All lanes : IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution

Performed under reducing conditions.

Predicted band size: 74 kDa
Observed band size: 74 kDa
Additional bands at: 100 kDa, 45 kDa, 70 kDa (possible degradation product). We are unsure as to the identity of these extra bands.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit **https://www.abcam.com/abpromise** or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors